Suppr超能文献

评估与健康相关政策时考虑时间因素。

Accounting for Timing when Assessing Health-Related Policies.

作者信息

Claxton Karl, Asaria Miqdad, Chansa Collins, Jamison Julian, Lomas James, Ochalek Jessica, Paulden Mike

机构信息

The London School of Economics and Political Science (LSE), Amrita Institute of Medical Sciences and Research Centre, London WC2A 2AE, UK, e-mail:

World Bank Group, Lusaka 10101, Zambia, e-mail:

出版信息

J Benefit Cost Anal. 2019 Jan 26;10(Suppl 1):73-105. doi: 10.1017/bca.2018.29.

Abstract

The primary focus of this paper is to offer guidance on the analysis of time streams of effects that a project may have so that they can be discounted appropriately. This requires a framework that identifies the common parameters that need to be assessed, whether conducting cost-effectiveness or benefit-cost analysis. The quantification and conversion of the time streams of different effects into their equivalent health, health care cost or consumption effects avoids embedding multiple arguments in discounting policies. This helps to identify where parameters are likely to differ in particular contexts, what type of evidence would be relevant, what is currently known and how this evidence might be strengthened. The current evidence available to support the assessment of the key parameters is discussed and possible estimates and default assumptions are suggested. Reporting the results in an extensive way is recommended. This makes the assessments required explicit so the impact of alternative assumptions can be explored and analysis updated as better estimates evolve. Some projects will have effects across different countries where some or all of these parameters will differ. Therefore, the net present value of a project will be the sum of the country specific net present values rather than the sum of effects across countries discounted at some common rate.

摘要

本文的主要重点是为分析项目可能产生的效果的时间流提供指导,以便能够对其进行适当的贴现。这需要一个框架,该框架能识别出无论进行成本效益分析还是效益成本分析都需要评估的共同参数。将不同效果的时间流量化并转换为其等效的健康、医疗成本或消费效果,可避免在贴现政策中嵌入多个论据。这有助于确定在特定背景下哪些参数可能不同、何种类型的证据会相关、目前已知的情况以及如何加强这一证据。本文讨论了目前可用于支持关键参数评估的证据,并提出了可能的估计值和默认假设。建议以详尽的方式报告结果。这使得所需的评估变得明确,从而能够探究替代假设的影响,并随着更好的估计值的出现而更新分析。一些项目会在不同国家产生效果,其中部分或所有这些参数会有所不同。因此,项目的净现值将是各国特定净现值的总和,而非以某个共同比率对各国效果进行贴现后的总和。

相似文献

1
Accounting for Timing when Assessing Health-Related Policies.评估与健康相关政策时考虑时间因素。
J Benefit Cost Anal. 2019 Jan 26;10(Suppl 1):73-105. doi: 10.1017/bca.2018.29.
4
5
8

引用本文的文献

本文引用的文献

1
Valuing Mortality Risk Reductions in Global Benefit-Cost Analysis.在全球效益成本分析中评估死亡率风险降低情况。
J Benefit Cost Anal. 2019;10(Suppl 1):15-50. doi: 10.1017/bca.2018.26. Epub 2019 Jan 15.
8
On the Estimation of the Cost-Effectiveness Threshold: Why, What, How?关于成本效益阈值的估计:为何、是什么、如何?
Value Health. 2016 Jul-Aug;19(5):558-66. doi: 10.1016/j.jval.2016.02.020. Epub 2016 Apr 23.
9
Determinants of Change in the Cost-effectiveness Threshold.成本效益阈值变化的决定因素。
Med Decis Making. 2017 Feb;37(2):264-276. doi: 10.1177/0272989X16662242. Epub 2016 Sep 27.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验